Entering text into the input field will update the search result below

NanoViricides up 85% premarket on license deal for VZV

Feb. 26, 2019 8:37 AM ETNanoViricides, Inc. (NNVC) StockBy: Douglas W. House, SA News Editor8 Comments
  • Thinly traded nano cap NanoViricides (NYSE:NNVC) is up 85% premarket on increased volume in reaction to its agreement with TheraCour Pharma for a license to develop drugs against varicella zoster virus (VZV), the virus that causes chickenpox in children and shingles in adults.
  • Under the terms of the agreement, TheraCour will receive nothing upfront, but will receive 500K shares of NNVC Series A Preferred Stock when it files an IND for its candidate NV-HHV-101. It will receive a $1.5M cash payment when NNVC completes Phase 1 development, followed by a $2.5M milestone when NNVC completes Phase 2. It will also earn a 15% royalty on net sales and 15% of any sub-licensing revenue.

Recommended For You

About NNVC Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NNVC--
NanoViricides, Inc.